Please ensure Javascript is enabled for purposes of website accessibility

3 Stocks That Could Put Nvidia's Returns to Shame

By Travis Hoium, Timothy Green, and Cory Renauer - Jul 25, 2017 at 6:30AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Stocks with the potential for returns anywhere near what NVIDIA has given in the last few years are rare, but we have three picks that have the potential for massive increases.

NVIDIA Corporation (NVDA -0.86%) has been one of the best stocks on the market the last few years, rising 205% over the past year and 820% over the last three years alone. You may have missed out, but every once in a while these kinds of game changing stocks pop up for investors. 

We asked a few of our investors for the stock they think could have NVIDIA-like returns and Fitbit Inc (FIT), General Motors Company (GM 1.34%), and Omeros Corporation (OMER -3.48%) made the top of the list. Here's why we like them so much. 

Man wearing smartwatch.

Image source: Getty Images.

A stock left for dead

Tim Green (Fitbit): There's more than one way for a stock to post incredible returns. NVIDIA has soared thanks to every part of its business growing like gangbusters, along with a heaping tablespoon of pie-in-the-sky expectations involving artificial intelligence and self-driving cars. Fitbit stock, if it follows suit, will rise not because the company is wildly successful, but because it doesn't fail.

FIT Chart

FIT data by YCharts

Fitbit stock has been decimated since the fitness wearables company went public in 2015, down nearly 90% from its peak. Revenue has tumbled, profits have turned into losses, and a reportedly troubled smartwatch project may not be the savior the company desperately needs. After a hiring binge throughout its time as a public company, Fitbit was forced to reverse course and lay off employees earlier this year.

With the stock down so much, and with expectations so low, any positive development could send the stock soaring. One thing helping the cause is Fitbit's balance sheet. At the end of the latest quarter, Fitbit had $725 in cash and no debt. Backing out the net cash, the market is valuing Fitbit's business at roughly $600 million. The company expects to produce at least $1.5 billion of revenue in 2017, although a substantial loss is also expected.

Fitbit needs to return to growth and profitability for the stock to have any chance of recovering. But if the company can exceed the beaten-down expectations of the market, a big gain for patient investors isn't out of the question.

A rare gem

Cory Renauer (Omeros Corporation): This biotech has a rare disease drug in development that could render its stock chart into the shape of a hockey stick. The candidate, tentatively named OMS721, throws a wrench in the works of a complex series of steps that can lead to the uncontrolled destruction of tiny blood vessels. The normal function of this component of the immune system removes foreign particles. Among a small group of patients with rare genetic conditions, though, uncontrolled activation of the complement system leads to life threatening clots within tiny blood vessels throughout the body.

There is a treatment available for one of these genetic conditions, atypical hemolytic uremic syndrome (aHUS), called Soliris from Alexion Pharmaceuticals. Unfortunately for aHUS patients it often causes headaches, diarrhea, and has been known to increase the risk of dangerous infections. Despite Soliris' drawbacks, it raked in a stunning $2.6 billion last year, and it stands to reason that a more tolerable treatment for inherited complement system disorders could top this figure.

Omeros Corporation's stock price has more than doubled this year, as the company dropped hints an ongoing clinical trial with aHUS patients designed to support an FDA application could succeed. A relative lack of side effects compared to Soliris could make a potential new drug launch incredibly successful, provided it earns FDA approval. If OMS721 becomes half as successful as Soliris, this company's market cap of just $965 million would probably swell to several times its current size.

Perhaps my favorite feature of this biotech is that it already has a growing source of revenue to fund OMS721's clinical trials. The company markets a pupil dilator called Omidria, and it's becoming increasingly popular among eye surgeons that perform millions of cataract removals and lens replacement surgeries each year. Omidria's ability to reduce complications has sent its sales surging to a level could make Omeros a profitable company this year, which could limit losses if an unexpected snafu causes OMS721 to fizzle.

Autonomous Chevy Bolt being introduced by GM.

Image source: General Motors.

The overlooked auto giant

Travis Hoium (General Motors): I'm going with an outside the box pick here, but let me explain why General Motors will be a great stock for investors long-term, just like Nvidia. 

GM is an extremely profitable company because of its core automotive operations. It's a leader in the lucrative truck and SUV market, something that's churning out cash today. And the stock trades at a price/earnings multiple below 6. 

GM Net Income (TTM) Chart

GM Net Income (TTM) data by YCharts

And GM is arguably doing more than any other company to build the autonomous fleets that will drive the future of transportation. Its Cruise Automation division is developing self-driving technology and if you watch its YouTube channel the results are pretty impressive and the all-electric Chevy Bolt has at least 180 autonomous vehicles in testing across the country. On top of Cruise Automation, GM owns a 9% stake in Lyft, the ride hailing company, giving it a lot of optionality in the autonomous driving future. 

On top of being a leader in autonomy and ride sharing, GM beat Tesla's (TSLA -2.62%) Model 3 to market when the Chevy Bolt hit the streets late last year. According to InsideEVs, GM has already sold 7,592 Bolts in the U.S. and is ramping up production each month. 

With a profitable foundation and a strategic position that puts it ahead of most competitors in EVs, autonomous driving, and ride sharing, GM is well positioned for the future. And shares are trading at such a low multiple that the stock could double and it could still be considered a value stock. Long-term, GM is a stock that could put Nvidia's returns to shame.

Cory Renauer has no position in any stocks mentioned. Timothy Green owns shares of General Motors. Travis Hoium has no position in any stocks mentioned. The Motley Fool owns shares of and recommends Fitbit and Tesla. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

General Motors Company Stock Quote
General Motors Company
$38.46 (1.34%) $0.51
Omeros Corporation Stock Quote
Omeros Corporation
$7.20 (-3.48%) $0.26
Fitbit, Inc. Stock Quote
Fitbit, Inc.
NVIDIA Corporation Stock Quote
NVIDIA Corporation
$179.42 (-0.86%) $-1.55
Tesla, Inc. Stock Quote
Tesla, Inc.
$859.89 (-2.62%) $-23.18

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/11/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.